Tyra Biosciences, Inc. (TYRA)

NMS – Real Time Price. Currency in USD

25.30

+0.12 (0.46%)

At close: Aug 12, 2026, 3:59 PM EDT

24.95

-0.35 (-1.38%)

After-hours: Aug 12, 2026, 4:48 PM EDT

10.08.2026

Tyra Biosciences: SURF302 Is A Worthwhile Binary Bet

TYRA's dabogratinib has an upcoming readout in September 2026 that I think could validate its FGFR3 profile. However, if they succeed with that trial, I believe it would also help TYRA's broader SNAP drug-design platform. In that sense, a strong, complete-response signal with a good safety profile could de-risk dabogratinib and improve TYRA's risk-reward profile as a whole.

04.08.2026

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) - - Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5th dose level, now expected end of Q1 2027 - - Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy - - Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 - CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate progress.

Videos

No Data

There is no data to display

Press releases

04.08.2026

Tyra Biosciences, Inc. (TYRA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Tyra Biosciences, Inc. (TYRA)

Tyra Biosciences: SURF302 Is A Worthwhile Binary Bet

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Videos

No Data

Press releases

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tyra Biosciences: SURF302 Is A Worthwhile Binary Bet

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Videos

No Data

Press releases

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Search stocks

Tyra Biosciences, Inc. (TYRA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Tyra Biosciences, Inc. (TYRA)

Tyra Biosciences: SURF302 Is A Worthwhile Binary Bet

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Videos

No Data

Press releases

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tyra Biosciences: SURF302 Is A Worthwhile Binary Bet

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Videos

No Data

Press releases

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights